Rapport Therapeutics Inc (RAPP)

Mar 13, 2025

Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock - Investing.com

Mar 13, 2025

Mar 13, 2025

Rapport Therapeutics director Wendy Young acquires $61,249 in stock - Investing.com

Mar 13, 2025

Mar 11, 2025

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 11, 2025

Mar 11, 2025

Rapport Therapeutics Reports Q4 Net Loss Of $19.98 Mln - Nasdaq

Mar 11, 2025

Mar 11, 2025

Rapport Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 11, 2025

Mar 11, 2025

Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year - TipRanks

Mar 11, 2025

Mar 11, 2025

Rapport Therapeutics Inc Q4 Net Loss $20.0 Million -March 11, 2025 at 07:20 am EDT - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Rhumbline Advisers Has $182,000 Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Mar 11, 2025

Mar 07, 2025

New York State Common Retirement Fund Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Mar 07, 2025

Mar 05, 2025

(RAPP) On The My Stocks Page - Stock Traders Daily

Mar 05, 2025

Mar 03, 2025

Rapport Therapeutics appoints new chief medical officer By Investing.com - Investing.com Canada

Mar 03, 2025

Mar 03, 2025

Rapport Therapeutics, Inc. Announces Appointment of Jeffrey Sevigny as Chief Medical Officer - Marketscreener.com

Mar 03, 2025

Mar 03, 2025

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development - The Manila Times

Mar 03, 2025

Mar 03, 2025

Rapport Therapeutics appoints new chief medical officer - Investing.com

Mar 03, 2025

Mar 03, 2025

Rapport Therapeutics Announces Appointment of Dr. Jeffrey - GlobeNewswire

Mar 03, 2025

Feb 24, 2025

Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Feb 24, 2025

Feb 22, 2025

Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World

Feb 22, 2025

Feb 20, 2025

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat

Feb 20, 2025

Feb 13, 2025

Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat

Feb 13, 2025

Feb 12, 2025

How To Trade (RAPP) - Stock Traders Daily

Feb 12, 2025

Feb 11, 2025

Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat

Feb 11, 2025

Feb 10, 2025

Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat

Feb 10, 2025

Feb 05, 2025

Rapport Therapeutics (NASDAQ:RAPP) Short Interest Down 15.3% in January - MarketBeat

Feb 05, 2025

Feb 04, 2025

JPMorgan Chase & Co. Purchases Shares of 4,033 Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Feb 04, 2025

Feb 03, 2025

Rapport Therapeutics (NASDAQ:RAPP) Trading Up 4.6%Here's What Happened - MarketBeat

Feb 03, 2025

Feb 02, 2025

J&J-backed Rapport Therapeutics files for $100M IPO - MSN

Feb 02, 2025

Feb 01, 2025

Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Feb 01, 2025

Jan 31, 2025

(RAPP) Proactive Strategies - Stock Traders Daily

Jan 31, 2025

Jan 31, 2025

Rapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on Thursday - Defense World

Jan 31, 2025

Jan 24, 2025

‘A really rational IPO environment’: What does it takes for a biotech to go public now? - Fierce Biotech

Jan 24, 2025

Jan 21, 2025

Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World

Jan 21, 2025

Jan 14, 2025

Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month LowWhat's Next? - MarketBeat

Jan 14, 2025

Jan 13, 2025

Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownWhat's Next? - MarketBeat

Jan 13, 2025

Jan 12, 2025

Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World

Jan 12, 2025

Jan 10, 2025

Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%What's Next? - MarketBeat

Jan 10, 2025

Jan 10, 2025

(RAPP) Technical Data - Stock Traders Daily

Jan 10, 2025

Jan 10, 2025

Rapport Therapeutics announces new Phase 1 data for RAP-219 - Yahoo Finance

Jan 10, 2025

Jan 10, 2025

Odyssey hires Jason Haas as CFO - BioCentury

Jan 10, 2025

Jan 09, 2025

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times

Jan 09, 2025

Jan 09, 2025

CORRECTION -- Rapport Therapeutics Announces New Phase 1 - GlobeNewswire

Jan 09, 2025

Jan 09, 2025

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times

Jan 09, 2025

Jan 09, 2025

Rapport Therapeutics Announces New Phase 1 Data, Further - GlobeNewswire

Jan 09, 2025

Jan 09, 2025

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - GlobeNewswire Inc.

Jan 09, 2025